Rate of return on biopharma R&D late stage pipeline 2013-2023
This statistic shows the internal rate of return (IRR) on biopharmaceutical late-stage R&D pipeline from 2013 to 2023. The data is based on the leading 20 biopharma companies by R&D spending. The rate of return decreased fluctuated during the whole period. The last year, 2023, showed a significantly larger growth than the previous year.